| 摘要 |
Disclosed are compounds of Formula (Ia), salts thereof and methods for their preparation. Specific examples of compounds of Formula (Ia) include: methyl N-[(2S)-1-({ 4-[3-(3-chloro-5-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl} amino)propan-2-yl] carbamate, methyl N-[(2S)-1-{ [4-(3-{ 2-fluoro-3-[(3,3,3-trifluoropropane)sulfonamido]phenyl} -1-(propan-2-yl)-1H-pyrazol-4-yl)pyrimidin-2-yl]amino} propan-2-yl] carbamate, N-[5-chloro-3-(4-{ 2-[(2-cyanoethyl)amino]pyrimidin-4-yl} -1-(propan-2-yl)-1H-pyrazol-3-yl)-2-fluorophenyl]methanesulfonamide, and methyl N-[(2S)-I-( { 4-[3-(S-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl} amino)propan-2-yl]carbamate. Compounds of formula Ia are useful for treating diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases of disorders that inveolve abnormal activation of B-Raf. Examples of diseases include lung carcinoma, pancreatic carcinoma, bladder carcinoma, colon carcinoma, and myeloid disorders, prostate cancer, thyroid cancer, melanoma, adenomas and carcinomas of the ovary, eye, liver, biliary tract, and nervous system. |
